Genentech, Inc. Phase II CT-388 Cuts HbA1c 2.65%, 15.5% Weight Loss

Genentech reported Phase II topline results for enicepatide (CT-388) in T2D: HbA1c fell 2.65% at the 24 mg dose, 90% reached ≤6.5%, 62% achieved <5.7%, and mean weight loss was 15.5% at 48 weeks. Safety was consistent with incretins; AE discontinuations were 2.0%.Material DetailsContext by AI Analy…